PURE News

EL CAJON, Calif.--(BUSINESS WIRE)-- #Antimicrobial--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025. Summary of Results of Operations – Fiscal Third Quarter Net product sales were $489,000 and $440,000 for the fiscal third quarter ended April 30, 2025 and 2024, respectively. The increase of $49,000 was attributable to increased s